OCULAR THERAPEUTIX INC's ticker is OCUL and the CUSIP is 67576A100. A total of 114 filers reported holding OCULAR THERAPEUTIX INC in Q3 2023. The put-call ratio across all filers is 0.46 and the average weighting 0.9%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $393 | +207.0% | 125,200 | +403.0% | 0.00% | – |
Q2 2023 | $128 | -65.9% | 24,893 | -65.0% | 0.00% | – |
Q1 2023 | $375 | -54.6% | 71,193 | -75.8% | 0.00% | -100.0% |
Q4 2022 | $826 | -98.6% | 293,993 | +1887.4% | 0.00% | – |
Q3 2022 | $61,000 | -96.0% | 14,793 | -96.1% | 0.00% | -100.0% |
Q2 2022 | $1,534,000 | -39.3% | 381,500 | -25.3% | 0.00% | -33.3% |
Q1 2022 | $2,528,000 | +353.0% | 510,805 | +537.7% | 0.00% | +200.0% |
Q4 2021 | $558,000 | -77.3% | 80,100 | -67.5% | 0.00% | -66.7% |
Q3 2021 | $2,462,000 | -46.9% | 246,200 | -24.7% | 0.00% | -50.0% |
Q2 2021 | $4,639,000 | +466.4% | 327,122 | +555.6% | 0.01% | +500.0% |
Q1 2021 | $819,000 | -88.2% | 49,900 | -85.1% | 0.00% | -87.5% |
Q4 2020 | $6,915,000 | +738.2% | 334,066 | +275.8% | 0.01% | +700.0% |
Q1 2017 | $825,000 | -32.0% | 88,900 | -38.7% | 0.00% | -50.0% |
Q4 2016 | $1,214,000 | +418.8% | 145,100 | +206.8% | 0.00% | – |
Q2 2016 | $234,000 | +1.3% | 47,300 | +330.3% | 0.00% | -100.0% |
Q2 2015 | $231,000 | – | 10,992 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
SUMMER ROAD LLC | 6,122,089 | $32,263 | 100.00% |
Opaleye Management Inc. | 6,105,900 | $32,178,093 | 9.64% |
DELTEC ASSET MANAGEMENT LLC | 1,913,612 | $10,084,735 | 2.49% |
Knoll Capital Management, LLC | 200,000 | $1,504,000 | 2.32% |
Endurant Capital Management LP | 512,744 | $2,702,161 | 1.39% |
Knoll Capital Management, LLC | 95,800 | $504,866 | 0.78% |
Covestor Ltd | 60,008 | $316 | 0.28% |
Ikarian Capital, LLC | 200,000 | $1,054,000 | 0.24% |
EAM Investors, LLC | 224,211 | $1,181,592 | 0.23% |
Nebula Research & Development LLC | 22,474 | $118,438 | 0.21% |